Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

6.120 +2.770 (+82.69%)

Official Closing Price Updated: 4:15 PM EDT, Jul 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	173,757,855
Open	5.420
Bid (Size)	6.070 (2,200)
Ask (Size)	6.090 (100)
Prev. Close	3.350
Today's Range	4.910 - 8.700
52wk Range	2.710 - 7.040
Shares Outstanding	348,875,959
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Which stocks are experiencing notable movement on Monday? ↗

Today 15:00 EDT

Via Chartmill

Discover the most active stocks in Monday's session. ↗

Today 14:00 EDT

Via Chartmill

Performance

YTD	+89.5%	+89.5%
1 Month	+85.5%	+85.5%
3 Month	+47.5%	+47.5%
6 Month	+44.0%	+44.0%
1 Year	-10.4%	-10.4%

More News

12 Health Care Stocks Moving In Monday's Intraday Session ↗

Today 13:05 EDT

Via Benzinga

Top stock movements in today's session. ↗

Today 12:30 EDT

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

Today 10:30 EDT

Via Chartmill

Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing ↗

Today 10:02 EDT

Via MarketBeat

Wondering what's happening in today's pre-market session? ↗

Today 8:30 EDT

Via Chartmill

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Today 6:00 EDT

From Agenus Inc.

Via Business Wire

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

July 06, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

June 25, 2026

From Agenus Inc.

Via Business Wire

Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves ↗

June 16, 2026

Via MarketBeat

Agenus Announces Virtual 2026 Annual Shareholders Meeting

June 02, 2026

From Agenus Inc.

Via Business Wire

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

May 21, 2026

From Agenus Inc.

Via Business Wire

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

May 21, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

May 15, 2026

From Agenus Inc.

Via Business Wire

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

May 11, 2026

From Agenus Inc.

Via Business Wire

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

May 04, 2026

From Agenus Bio

Via Business Wire

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

April 21, 2026

From Agenus Inc.

Via Business Wire

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

April 21, 2026

From Agenus Inc. & BAP Pharma

Via Business Wire

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

April 17, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

April 03, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

April 01, 2026

From Agenus Inc.

Via Business Wire

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

March 26, 2026

From Agenus Inc.

Via Business Wire

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

March 17, 2026

From Agenus Bio

Via Business Wire

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

March 16, 2026

From Agenus Inc.

Via Business Wire

Frequently Asked Questions

Is Agenus Inc. - Common Stock publicly traded?

Yes, Agenus Inc. - Common Stock is publicly traded.

What exchange does Agenus Inc. - Common Stock trade on?

Agenus Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Agenus Inc. - Common Stock?

The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market

What is the current price of Agenus Inc. - Common Stock?

The current price of Agenus Inc. - Common Stock is 6.120

When was Agenus Inc. - Common Stock last traded?

The last trade of Agenus Inc. - Common Stock was at 07/13/26 04:15 PM ET

What is the market capitalization of Agenus Inc. - Common Stock?

The market capitalization of Agenus Inc. - Common Stock is 2.14B

How many shares of Agenus Inc. - Common Stock are outstanding?

Agenus Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.